NOV 22, 2017 6:38 PM PST

A Drug for Asthma Could Help Patients With Multiple Sclerosis

In the United States, approximately 400,000 people are living with Multiple Sclerosis (MS). Worldwide the number jumps to 2.5 million sufferers. What many don't realize is that geography can play a part in the disease, as the incidence of MS per 100,000 people is twice as high in northern areas above the 37th parallel compared to below that point. Rates rise as the distance from the equator grows.

The most devastating form of the disease is progressive MS, because it attacks the brain and spine, eventually leading to paralysis. Relapsing and remitting MS is a milder form. About half of the patients who have relapsing and remitting MS will ultimately develop the progressive form of the disease. MS is not fatal and most patients who have it die from complications such as pneumonia or infections. There is no cure for MS and treatments are not always effective. There is some hope, however, in the study of a drug used to treat asthma.

Ibudilast, a drug used in Japan to treat asthma has been studied as a possible treatment for MS. New research suggests that the drug, which is taken orally, can slow the brain damage that happens in the later stages of progressive MS.

Robert Fox, M.D., of Cleveland Clinic, was the lead author on the study and he explained in a press release, "What we found is ibudilast treatment was associated with a 48 percent slowing in the progression of brain shrinkage. It cut in half the progression of brain atrophy and brought the rate quite close to what we see in otherwise healthy people."

The only treatment approved for progressive MS is a course of chemotherapy. That protocol comes with risks and side effects that can make a patient feel worse than they do with MS. In the research into ibudilast, 255 patients with progressive MS were studied. Half received the drug, and half received a placebo. All underwent MRI scans, and their progress was followed for two years. The results showed a significant slowing of brain atrophy. Dr. Fox hopes that further trials of the drug will show that it could also be effective in slowing progression of the disease in the body. In the later stages of MS, muscles stop working, there can be a loss of sensation in the arms or legs, and vision disruptions can occur. If ibudilast turns out to slow this progression as well as it did for the brain, it could be a real game-changer for patients.

Dr. Fox said a more extensive trial would be needed to see if the drug can do even more than it's already done, stating, "That is going to require another trial, a much larger trial, to look at whether this drug is truly beneficial on the progression of disability. The hope though is that its benefit in slowing progression of brain atrophy will translate to a slowing in the progression of disability as well."

Check out the video for more information.

Sources: Cleveland Clinic, Fierce BioTech, National MS Society

About the Author
  • I'm a writer living in the Boston area. My interests include cancer research, cardiology and neuroscience. I want to be part of using the Internet and social media to educate professionals and patients in a collaborative environment.
You May Also Like
SEP 28, 2021
Clinical & Molecular DX
Black College Football Players More at Risk of Heart Conditions
SEP 28, 2021
Black College Football Players More at Risk of Heart Conditions
College football players may have an elevated risk of developing a heart condition where the left side of the heart beco ...
SEP 28, 2021
Drug Discovery & Development
The FDA approves drug to treat a bad cholesterol in children
SEP 28, 2021
The FDA approves drug to treat a bad cholesterol in children
Familial hypercholesterolemia (FH) is a genetic disorder that afflicts approximately 1 in 250 people. Interestingly, whi ...
OCT 03, 2021
Coronavirus
Merck's COVID-19 Drug Halves Risk of Death in Mild & Moderate Cases
OCT 03, 2021
Merck's COVID-19 Drug Halves Risk of Death in Mild & Moderate Cases
While Dr. Anthony Fauci of NIAID is already stressing that people should still get vaccinated to help reduce COVID-19 in ...
OCT 05, 2021
Immunology
Inflammation Overload Triggers 'Microclots' in COVID Long-Haulers
OCT 05, 2021
Inflammation Overload Triggers 'Microclots' in COVID Long-Haulers
Months after COVID symptoms have subsided, some individuals continue to grapple with the lingering effects of the infect ...
OCT 06, 2021
Genetics & Genomics
Signs of Huntington's Disease in Early Embryonic Development
OCT 06, 2021
Signs of Huntington's Disease in Early Embryonic Development
Huntington's disease is a neurodegenerative disorder that's caused by mutations in the huntingtin gene. People can be di ...
OCT 21, 2021
Microbiology
Ongoing Salmonella Outbreak Traced to Onions
OCT 21, 2021
Ongoing Salmonella Outbreak Traced to Onions
On October 20, 2021, the Centers for Disease Control and Prevention (CDC) announced that an outbreak of Salmonella food ...
Loading Comments...